Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
ConditionUrothelial Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorPeking University Cancer Hospital & Institute
About this trial
To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
18-75 years old, male or female;
Heart function is normal;
Normal heart function;
Estimated survival ≥12 weeks;
Disqualifiers
Serious abnormality of liver, kidney and blood;
Pregnant patients;
Pregnant and lactation women;
Trial design
Design model
Single group
Treatments tested in this trial
18F-FDG
DrugAll study participants will undergo one 18F-FDG PET/CT scan.
Treatment groups
20 Participants
are divided into 1 treatment groupGroup A: 68Ga-N188Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Standardized uptake value（SUV）
SUV is a semi-quantitative analysis index to describe the radioactive uptake of lesions, which has certain reference value for differentiating benign and malignant lesions。 The uptake of the tracer （68Ga-N188） in urothelial carcinoma tumor lesions by measuring SUV on PET/CT.
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov